Drugs that change patients' lives
Explore All Products →Our biologic medicines have received approvals in markets including China, the United States and the European Union, spanning autoimmune diseases, oncology and cardiovascular disease.
Innovation for Life
Based on Guangzhou International Bio Island, we develop innovative medicines and biosimilars. Multiple products are approved in China, the United States, the EU and other markets.
+ Discover Bio-TheraJoin hands with the world's leading pharmaceutical companies to expand international markets
Explore Partnerships →Next-Generation Therapies
Explore Our Pipeline →Advancing innovative medicines and biosimilars, with a focus on ADCs and candidates for autoimmune diseases.
Technology
From antibody discovery and engineering to ADCs and commercial manufacturing, our integrated capabilities support the development of innovative medicines and biosimilars.
+ Explore technology platforms
Manufacturing & Quality
A quality management system that meets the GMP requirements of the United States, the European Union, and China has been established. The company has built an industrialization base that complies with China's NMPA, US FDA, European EMA and Brazilian ANVISA standards.
Based on the ICH Q10 model, quality management spans research and development, technology transfer, commercial production and product discontinuation.
+ Explore furtherCompany News
+ Read all newsR&D Updates
+ View all information-
June 2, 2026
Bio-Thera Presents Latest Oncology Pipeline Data at the 2026 ASCO Annual Meeting
BAT8008 / BAT8006+BAT1308 / BAT8010+BAT1006 -
July 2, 2026
"Lancet Rheumatology"
BAT2306 phase III clinical study results released
Careers
The company has built a talent team with high academic level, wide professional coverage and strong technical force. Partners interested in antibody drug development and industrialization are welcome to join Bio-Thera.
